Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2022: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2020: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2019: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Outline of Final Research Achievements |
[18F]SMBT-1 was successfully developed for in vivo imaging of reactive astrogliosis in the human brain. In the clinical study, [18F]SMBT-1 PET showed positive findings not only in patients with Alzheimer's disease but also in amyloid-positive cognitively normal elderly. These findings suggest that the proliferation of reactive astrocytes is an early event that is closely associated with amyloid-beta accumulation in Alzheimer's disease continuum. We further developed a novel tau PET probe, [18F]SNFT-1. [18F]SNFT-1 showed high binding affinity and selectivity for tau aggregates in Alzheimer's disease brains, suggesting the potential usefulness for in vivo detection of early tau pathology.
|